Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clarion-CKD: KBP-5074 in Uncontrolled Hypertension and Moderate/Severe CKD
NCT04968184Phase 3Terminated
- Sponsor
- Novo Nordisk
- Start
- Nov 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) and chronic kidney disease (CKD) comparing Placebo with KBP-5074 (2 arms). Primary endpoint: Systolic Blood Pressure at 52 weeks. Started Nov 2021; status: terminated.
02
Drugs
ocederenone
03
Conditions
hypertension (HTN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04968184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968184.